Tarsus Pharmaceuticals (TARS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $68.07, -4.11% vs the prior close of $70.99.
- Volume 2.43M shares, 2.9x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TARS slides 4.1% to $68.07, a 1-month low on 2.9x normal volume. Closed at $68.07, -4.11% vs the prior close of $70.99. Day range $68.00–$70.87, opened at $70.87.
TARS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TARS slides 4.1% to $68.07, a 1-month low on 2.9x normal volume
- Closed at $68.07, -4.11% vs the prior close of $70.99. Day range $68.00–$70.87, opened at $70.87.
- Volume was 2.43M shares, 2.9x its 50-day average of 839.49K — unusually heavy trading.
- Price is -9.0% vs its 50-day average ($74.83) and -0.1% vs its 200-day average ($68.12).
- 52-week range $53.89–$91.53; today's close sits at 38% of that range, 25.6% below the 52-week high.
Oct 15, 2026 — TARS dips 1.8% to $70.99
- Closed at $70.99, -1.80% vs the prior close of $72.29. Day range $70.55–$74.94, opened at $72.58.
- Volume was 1.40M shares, 1.7x its 50-day average of 818.61K.
- Price is -5.1% vs its 50-day average ($74.78) and +4.1% vs its 200-day average ($68.20).
- 52-week range $53.89–$91.53; today's close sits at 45% of that range, 22.4% below the 52-week high.
Oct 14, 2026 — TARS rises 2.1% to $72.29
- Closed at $72.29, +2.08% vs the prior close of $70.82. Day range $70.03–$73.35, opened at $70.57.
- Volume was 1.17M shares, 1.4x its 50-day average of 806.12K.
- Price is -3.1% vs its 50-day average ($74.58) and +5.9% vs its 200-day average ($68.25).
- 52-week range $53.89–$91.53; today's close sits at 49% of that range, 21.0% below the 52-week high.
Oct 13, 2026 — TARS slides 4.8% to $70.82, a 1-month low on 2.1x normal volume
- Closed at $70.82, -4.81% vs the prior close of $74.40. Day range $70.32–$75.02, opened at $74.50.
- Volume was 1.63M shares, 2.1x its 50-day average of 790.09K — unusually heavy trading.
- Price is -4.8% vs its 50-day average ($74.36) and +3.7% vs its 200-day average ($68.30).
- 52-week range $53.89–$91.53; today's close sits at 45% of that range, 22.6% below the 52-week high.
Oct 12, 2026 — TARS rises 1.7% to $74.40 on 1.9x normal volume
- Closed at $74.40, +1.69% vs the prior close of $73.16. Day range $72.97–$76.64, opened at $73.20.
- Volume was 1.46M shares, 1.9x its 50-day average of 773.57K — unusually heavy trading.
- Price is +0.3% vs its 50-day average ($74.17) and +8.8% vs its 200-day average ($68.36).
- 52-week range $53.89–$91.53; today's close sits at 54% of that range, 18.7% below the 52-week high.
Oct 9, 2026 — TARS rises 1.3% to $73.16
- Closed at $73.16, +1.30% vs the prior close of $72.22. Day range $71.20–$73.93, opened at $72.22.
- Volume was 481.80K shares, 0.6x its 50-day average of 777.91K.
- Price is -0.9% vs its 50-day average ($73.86) and +7.0% vs its 200-day average ($68.39).
- 52-week range $53.89–$91.53; today's close sits at 51% of that range, 20.1% below the 52-week high.
Oct 8, 2026 — TARS dips 1.9% to $72.22, a 1-month low, 3 down days in a row
- Closed at $72.22, -1.89% vs the prior close of $73.61. Day range $70.80–$74.51, opened at $73.07.
- Volume was 642.10K shares, 0.8x its 50-day average of 778.67K.
- Price is -1.9% vs its 50-day average ($73.59) and +5.5% vs its 200-day average ($68.44).
- 52-week range $53.89–$91.53; today's close sits at 49% of that range, 21.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — TARS dips 0.7% to $73.61
- Closed at $73.61, -0.67% vs the prior close of $74.11. Day range $73.30–$74.68, opened at $73.58.
- Volume was 542.30K shares, 0.7x its 50-day average of 778.02K.
- Price is +0.4% vs its 50-day average ($73.31) and +7.5% vs its 200-day average ($68.48).
- 52-week range $53.89–$91.53; today's close sits at 52% of that range, 19.6% below the 52-week high.
Oct 6, 2026 — TARS dips 0.5% to $74.11
- Closed at $74.11, -0.46% vs the prior close of $74.46. Day range $72.94–$75.25, opened at $74.48.
- Volume was 432.40K shares, 0.6x its 50-day average of 783.88K — lighter than usual.
- Price is +1.5% vs its 50-day average ($73.02) and +8.2% vs its 200-day average ($68.50).
- 52-week range $53.89–$91.53; today's close sits at 54% of that range, 19.0% below the 52-week high.
Oct 5, 2026 — TARS rises 2.0% to $74.46
- Closed at $74.46, +1.99% vs the prior close of $73.00. Day range $72.76–$75.00, opened at $73.22.
- Volume was 939.60K shares, 1.2x its 50-day average of 774.02K.
- Price is +2.4% vs its 50-day average ($72.74) and +8.7% vs its 200-day average ($68.52).
- 52-week range $53.89–$91.53; today's close sits at 55% of that range, 18.7% below the 52-week high.
Oct 2, 2026 — TARS slides 3.3% to $73.00, a 1-month low
- Closed at $73.00, -3.26% vs the prior close of $75.46. Day range $72.94–$75.84, opened at $75.84.
- Volume was 1.21M shares, 1.6x its 50-day average of 771.69K.
- Price is +0.8% vs its 50-day average ($72.43) and +6.5% vs its 200-day average ($68.54).
- 52-week range $53.89–$91.53; today's close sits at 51% of that range, 20.2% below the 52-week high.
TARS latest news & SEC filings
Every SEC filing by or about TARS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 13, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 13, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pyott David E I converted options/RSUs into 201 shares on Sep 15, 2026; now holds 9,575
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Yarno Wendy L converted options/RSUs into 302 shares on Sep 15, 2026; now holds 16,956
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Link William J Phd converted options/RSUs into 201 shares on Sep 15, 2026; now holds 106,987
- Link William J Phd sold 11,675 shares at $78.33 (≈$914.50K) on Sep 15, 2026; now holds 95,312
- Link William J Phd sold 759 shares at $79.00 (≈$59.96K) on Sep 15, 2026; now holds 94,553
- Link William J Phd sold 66 shares at $80.01 (≈$5.28K) on Sep 15, 2026; now holds 94,487
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 8.01 — Reported other events the company considers important.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Azamian Bobak R. sold 2,900 shares at $91.27 (≈$264.68K) on Sep 4, 2026
- Azamian Bobak R. sold 7,100 shares at $90.27 (≈$640.92K) on Sep 4, 2026
- Azamian Bobak R. sold 2,900 shares at $91.27 (≈$264.68K) on Sep 4, 2026
- Azamian Bobak R. sold 7,100 shares at $90.27 (≈$640.92K) on Sep 4, 2026
- Azamian Bobak R. sold 2,900 shares at $91.27 (≈$264.68K) on Sep 4, 2026
- Azamian Bobak R. sold 7,100 shares at $90.27 (≈$640.92K) on Sep 4, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lin Elizabeth Yeu sold 1,590 shares at $85.00 (≈$135.15K) on Sep 4, 2026
- Lin Elizabeth Yeu sold 1,590 shares at $90.00 (≈$143.10K) on Sep 4, 2026
- Lin Elizabeth Yeu sold 5,387 shares at $85.00 (≈$457.89K) on Sep 4, 2026
- Lin Elizabeth Yeu sold 5,386 shares at $90.00 (≈$484.74K) on Sep 4, 2026
- Lin Elizabeth Yeu sold 1,590 shares at $85.00 (≈$135.15K) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $173.91M (prior year $102.66M) (+69.4% vs Jun 30, 2025)
- Net income: -$18.55M (prior year -$20.34M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.43 (prior year -$0.48) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade TARS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 23, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.99% (largest 4.8%).
- Liquidity: about 993.38K shares (≈$67.62M) trade per day on average.
- 52-week position: $68.07 vs a range of $53.89–$91.53 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: William J Phd Link sold 66 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 10, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 43.88M shares outstanding (Jul 30, 2026), +4.0% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
TARS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 70.87 | 70.87 | 68.00 | 68.07 | 2.43M |
| Oct 15, 2026 | 72.58 | 74.94 | 70.55 | 70.99 | 1.40M |
| Oct 14, 2026 | 70.57 | 73.35 | 70.03 | 72.29 | 1.17M |
| Oct 13, 2026 | 74.50 | 75.02 | 70.32 | 70.82 | 1.63M |
| Oct 12, 2026 | 73.20 | 76.64 | 72.97 | 74.40 | 1.46M |
| Oct 9, 2026 | 72.22 | 73.93 | 71.20 | 73.16 | 481.80K |
| Oct 8, 2026 | 73.07 | 74.51 | 70.80 | 72.22 | 642.10K |
| Oct 7, 2026 | 73.58 | 74.68 | 73.30 | 73.61 | 542.30K |
| Oct 6, 2026 | 74.48 | 75.25 | 72.94 | 74.11 | 432.40K |
| Oct 5, 2026 | 73.22 | 75.00 | 72.76 | 74.46 | 939.60K |
| Oct 2, 2026 | 75.84 | 75.84 | 72.94 | 73.00 | 1.21M |
| Oct 1, 2026 | 78.45 | 79.10 | 75.03 | 75.46 | 1.24M |
| Sep 30, 2026 | 76.76 | 78.70 | 76.32 | 78.61 | 1.56M |
| Sep 29, 2026 | 76.22 | 77.99 | 75.53 | 76.69 | 418.00K |
| Sep 28, 2026 | 75.83 | 76.82 | 74.66 | 76.81 | 1.31M |
| Sep 25, 2026 | 75.78 | 76.17 | 73.85 | 75.69 | 721.40K |
| Sep 24, 2026 | 75.33 | 77.91 | 74.44 | 75.96 | 598.50K |
| Sep 23, 2026 | 77.18 | 77.61 | 74.20 | 74.29 | 674.30K |
| Sep 22, 2026 | 77.61 | 78.59 | 76.01 | 77.08 | 517.00K |
| Sep 21, 2026 | 78.09 | 78.57 | 76.39 | 77.46 | 487.10K |
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals (TARS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in IRVINE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1819790.
TARS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair | Sep 9, 2026 |
| Bhaskar Chaudhuri | Director | Jun 29, 2026 |
| Andrew D. Goldberg | Director | Jun 29, 2026 |
| Katherine Goodrich | Director | Jun 29, 2026 |
| William J Phd Link | Director | Sep 17, 2026 |
| Scott W Morrison | Director | Jun 29, 2026 |
| David E I Pyott | Director | Sep 17, 2026 |
| Wendy L Yarno | Director | Sep 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair | Sep 9, 2026 |
| Jeffrey S Farrow | See Remarks | Jun 17, 2026 |
| Elizabeth Yeu Lin | Chief Medical Officer | Sep 9, 2026 |
| Aziz Mottiwala | Chief Commercial Officer | Mar 19, 2026 |
| Seshadri Neervannan | Chief Operating Officer | Sep 9, 2026 |
| Bryan Wahl | General Counsel | Mar 19, 2026 |
| Dianne C. Whitfield | Chief Human Resources Officer | Mar 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | William J Phd Link | Sale | 66 | $80.01 |
| Sep 15, 2026 | William J Phd Link | Sale | 759 | $79.00 |
| Sep 15, 2026 | William J Phd Link | Sale | 11,675 | $78.33 |
| Sep 15, 2026 | William J Phd Link | Sale | 66 | $80.01 |
| Sep 15, 2026 | William J Phd Link | Sale | 759 | $79.00 |
| Sep 15, 2026 | William J Phd Link | Sale | 11,675 | $78.33 |
| Sep 15, 2026 | William J Phd Link | Sale | 66 | $80.01 |
| Sep 15, 2026 | William J Phd Link | Sale | 759 | $79.00 |
| Sep 15, 2026 | William J Phd Link | Sale | 11,675 | $78.33 |
| Sep 15, 2026 | William J Phd Link | Sale | 66 | $80.01 |
| Sep 15, 2026 | William J Phd Link | Sale | 759 | $79.00 |
| Sep 15, 2026 | William J Phd Link | Sale | 11,675 | $78.33 |
| Sep 4, 2026 | Bobak R. Azamian | Sale | 2,900 | $91.27 |
| Sep 4, 2026 | Bobak R. Azamian | Sale | 7,100 | $90.27 |
| Sep 4, 2026 | Bobak R. Azamian | Sale | 2,900 | $91.27 |
TARS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $451.36M | $-66.42M | -1.59 | $-12.45M |
| Dec 31, 2024 | $182.95M | $-115.55M | -3.07 | $-83.03M |
| Dec 31, 2023 | $17.45M | $-135.89M | -4.62 | $-117.49M |
| Dec 31, 2022 | $25.82M | $-62.09M | -2.52 | $-49.03M |
| Dec 31, 2021 | $57.03M | $-13.83M | -0.67 | $3.75M |
Latest balance sheet: total assets $611.14M, total liabilities $264.41M, cash $204.59M (as of Jun 30, 2026).
TARS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $65.33 |
| May 6, 2026 | 8-K Item 2.02 (results) | $64.76 |
| Feb 23, 2026 | 8-K Item 2.02 (results) | $69.59 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $71.50 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $41.64 |
| May 1, 2025 | 8-K Item 2.02 (results) | $50.30 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $41.29 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $46.51 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TARS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.